See more : Guoanda Co., Ltd. (300902.SZ) Income Statement Analysis – Financial Results
Complete financial analysis of Invitae Corporation (NVTAQ) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Invitae Corporation, a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.
- Trip Technologies Inc. (TRPS) Income Statement Analysis – Financial Results
- Vistas Media Acquisition Company Inc. (VMAC) Income Statement Analysis – Financial Results
- ADCapital US Inc. (ADCV) Income Statement Analysis – Financial Results
- MBL Infrastructures Limited (MBLINFRA.BO) Income Statement Analysis – Financial Results
- Companhia de Locação das Américas (LCAM3.SA) Income Statement Analysis – Financial Results
Invitae Corporation (NVTAQ)
About Invitae Corporation
Invitae Corporation, a medical genetics company, that provides genetic information to improve healthcare of people in the United States, Canada, and internationally. The company offers genetic tests in various clinical areas, including hereditary cancer, precision oncology, women's health, rare diseases, and pharmacogenomics; digital health solutions; and health data services. It serves patients, healthcare providers, biopharma companies, and other partners. The company was formerly known as Locus Development, Inc. and changed its name to Invitae Corporation in 2012. Invitae Corporation was incorporated in 2010 and is headquartered in San Francisco, California. On February 13, 2024, Invitae Corporation, along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of New Jersey.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 487.00M | 516.30M | 460.45M | 279.60M | 216.82M | 147.70M | 68.22M | 25.05M |
| Cost of Revenue | 234.43M | 417.00M | 350.87M | 202.97M | 121.38M | 80.11M | 51.94M | 27.88M |
| Gross Profit | 252.57M | 99.30M | 109.58M | 76.63M | 95.44M | 67.59M | 16.28M | -2.83M |
| Gross Profit Ratio | 51.86% | 19.23% | 23.80% | 27.41% | 44.02% | 45.76% | 23.86% | -11.30% |
| Research & Development | 0.00 | 394.19M | 363.51M | 239.79M | 141.06M | 63.50M | 46.47M | 44.63M |
| General & Administrative | 0.00 | 192.31M | 248.07M | 270.03M | 78.96M | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 218.88M | 225.91M | 168.32M | 122.24M | 0.00 | 0.00 | 0.00 |
| SG&A | 0.00 | 409.76M | 407.58M | 466.41M | 190.05M | 122.54M | 87.27M | 52.72M |
| Other Expenses | -77.12M | 8.05M | 482.00K | 5.20M | -3.89M | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 77.12M | 803.95M | 771.09M | 706.20M | 331.11M | 186.03M | 133.74M | 97.35M |
| Cost & Expenses | 311.55M | 1.22B | 1.12B | 909.17M | 452.49M | 266.14M | 185.68M | 125.23M |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 56.75M | 49.90M | 29.77M | 12.41M | 7.03M | 3.65M | 421.00K |
| Depreciation & Amortization | 0.00 | 147.44M | 76.90M | 37.10M | 14.80M | 13.54M | 9.18M | 6.55M |
| EBITDA | 175.45M | -2.95B | -285.49M | -645.45M | -231.80M | -104.90M | -108.28M | -93.63M |
| EBITDA Ratio | 36.03% | -107.92% | -126.96% | -211.90% | -101.86% | -71.02% | -158.71% | -373.80% |
| Operating Income | 175.45M | -704.65M | -661.50M | -629.57M | -235.67M | -118.44M | -117.46M | -100.18M |
| Operating Income Ratio | 36.03% | -136.48% | -143.66% | -225.17% | -108.69% | -80.19% | -172.17% | -399.96% |
| Total Other Income/Expenses | -175.45M | -2.45B | 245.64M | -84.70M | -24.75M | -13.72M | -7.78M | -73.00K |
| Income Before Tax | 0.00 | -3.15B | -415.86M | -714.27M | -260.42M | -132.16M | -125.24M | -100.26M |
| Income Before Tax Ratio | 0.00% | -610.34% | -90.32% | -255.46% | -120.10% | -89.48% | -183.57% | -400.26% |
| Income Tax Expense | 0.00 | -44.90M | -36.86M | -112.10M | -18.45M | -2.80M | -1.86M | 0.00 |
| Net Income | 0.00 | -3.11B | -379.01M | -602.17M | -241.97M | -129.35M | -123.38M | -100.26M |
| Net Income Ratio | 0.00% | -601.64% | -82.31% | -215.37% | -111.60% | -87.58% | -180.85% | -400.26% |
| EPS | 0.00 | -13.18 | -1.80 | -4.47 | -2.66 | -1.94 | -2.65 | -3.02 |
| EPS Diluted | 0.00 | -13.18 | -1.80 | -4.47 | -2.66 | -1.94 | -2.65 | -3.02 |
| Weighted Avg Shares Out | 275.60M | 235.68M | 210.95M | 134.59M | 90.86M | 66.75M | 46.51M | 33.18M |
| Weighted Avg Shares Out (Dil) | 275.60M | 235.68M | 210.95M | 134.59M | 90.86M | 66.75M | 46.51M | 33.18M |
Labcorp Finalizes Acquisition of Select Assets of Invitae
Invitae Launches Unlock™ Behind the Seizure® Program for Pediatric Epilepsy Patients
Source: https://incomestatements.info
Category: Stock Reports